ZOLL Enters Multi-Year Agreement to Add Masimo Rainbow Set Technology in E Series Defibrillators

"Masimo Rainbow SET Pulse CO-Oximetry non-invasively delivers the advanced clinical intelligence that today's EMS and fire professionals need to accurately diagnose and treat victims of carbon monoxide poisoning," said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. "This agreement will allow us to add this important parameter in the future to help rescuers advance their lifesaving efforts."

Carbon monoxide (CO) is a dangerous silent killer that is often very difficult to diagnose. If left untreated, it can have significant morbidity and mortality consequences. Masimo Rainbow SET has the potential to help clinicians improve patient outcomes through more rapid diagnosis of potentially life-threatening conditions--including carbon monoxide poisoning and methemoglobinemia--allowing them to make better and earlier treatment decisions.

Joe E. Kiani, Founder and CEO of Masimo, said, "We're pleased that ZOLL joins us in recognizing the important contribution the cutting-edge technology can make in saving lives."

Masimo Rainbow SET Pulse CO-Oximetry is the first-and-only technology platform capable of noninvasively and continuously measuring total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and pleth variability index (PVI(TM)), in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR). Masimo Rainbow SET--featuring the accuracy and reliability of Masimo SET(R) Measure-Through Motion and Low Perfusion pulse oximetry--significantly expands traditional noninvasive patient monitoring capabilities to quickly and easily measure, track and monitor blood constituents that previously required invasive procedures.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help(R) and See-Thru CPR(R), that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. 2008 marks the 25th anniversary of ZOLL's resuscitation product development. For more information, visit www.zoll.com.

About Masimo

Masimo (NASDAQ: MASI | Quote | Chart | News | PowerRating) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2008. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright (C) 2008 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, E Series, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE: ZOLL Medical Corporation

INVESTOR CONTACT: ZOLL Medical Corporation A. Ernest Whiton, +1 978-421-9655 Chief Financial Officer or MEDIA CONTACTS: ZOLL Medical Corporation Diane Egan, +1 978-421-9637 degan@zoll.com or Masimo Corporation Dana Banks, 949-297-7348